Serum-Biocon alliance to make India a global vaccine manufacturing powerhouse

Adar Poonawalla’s Serum Institute of India on Friday said that through the strategic alliance between Biocon Biologics and Serum Institue Life Sciences, it hopes to strengthen India’s position as a global vaccine and biologics manufacturing powerhouse.

Bengaluru-based biopharmaceutical company will get access to a 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialization rights of the SILS vaccine portfolio for global markets.


Leave a Reply

Your email address will not be published. Required fields are marked *